Alessio S.
- Country
- Italy
- Department
- Arcispedale Sant'Anna, Unità Operativa di Oncologia Clinica
Research Overview
- Efficacy and Safety of Giredestrant Plus Everolimus Versus Endocrine Therapy Plus Everolimus in ER-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3 Randomized, Double-Blind Study of Tucatinib with Trastuzumab and Pertuzumab in Maintenance Therapy for Metastatic HER2-Positive Breast Cancer
- Phase III Study on Palbociclib with Anti-HER2 and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer Post-Induction Treatment
Data & Insights
Has run more than one trial at 140 of 363 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in treating advanced and metastatic breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-positive/negative variants.
- Endocrine Therapy Optimization
- HER2-Targeted Treatments
- Novel Therapeutic Combinations
Their work encompasses innovative approaches for patients who have progressed on conventional treatments.
Triple-Negative Breast Cancer
Focused on developing treatments for triple-negative breast cancer, particularly investigating immunotherapy approaches and combination therapies.
- Immunotherapy Applications
- Chemotherapy Combinations
- High-Risk Patient Management
The research extends to both early-stage and metastatic settings of the disease.
Treatment Sequencing Strategies
Expertise in determining optimal treatment timing and sequences for breast cancer therapies, including adjuvant treatment approaches.
- Sequential vs. Concurrent Therapy
- Adjuvant Treatment Protocols
- Long-term Disease Management
Their work aims to establish more effective treatment protocols for various breast cancer subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.